Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study

Bone Marrow Transplantation volume 45, pages 1587–1593 (2010)Cite this article

Subjects

Abstract

Fifty-one patients with primary myelofibrosis (PMF) received allogeneic haematopoietic stem cell transplants from related (n=33) or unrelated (n=18) donors. Twenty-seven patients, 19–54 years old, were prepared with myeloablative regimens including CY plus BU (n=4) or TBI (n=23). Twenty-four patients, 40–64 years old, received reduced-intensity conditioning (RIC) regimens. All RIC regimens contained fludarabine, combined with melphalan (n=19) or BU (n=5), and alemtuzumab or anti-thymocyte globulin (ATG) in the majority (n=19). Four patients (17%) in the RIC group had primary graft failure. Previous splenectomy reduced time to engraftment in the RIC group (13 versus 20 days; P=0.008). For MA and RIC groups, respectively, at 3 years, overall survival rates were 44 and 31% (P=0.67), progression-free survival 44 and 24% (P=0.87), and actuarial relapse rates 15 and 46% (P=0.06). Non-relapse mortality at 3 years was 41% for the myeloablative and 32% for the RIC group. Acute GVHD occurred in 29 and 38% of patients in the myeloablative and RIC groups, respectively. Extensive chronic GVHD developed in 30 and 35% of evaluable patients, respectively.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Smith BD, Moliterno AR . Biology and management of idiopathic myelofibrosis. Curr Opin Oncol 2001; 13: 91–94.

    Article  CAS  Google Scholar 

  2. Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.

    Article  CAS  Google Scholar 

  3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.

    Article  CAS  Google Scholar 

  4. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.

    CAS  PubMed  Google Scholar 

  5. Bachleitner-Hofmann T, Gisslinger H . The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol 1999; 78: 533–538.

    Article  CAS  Google Scholar 

  6. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S et al. Low dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22: 424–431.

    Article  CAS  Google Scholar 

  7. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliot M, Kaufmann SH et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534–2541.

    Article  CAS  Google Scholar 

  8. Kroger N, Mesa RA . Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22: 474–486.

    Article  CAS  Google Scholar 

  9. Li Z, Gooley T, Applebaum FR, Deeg HJ . Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001; 97: 2180–2181.

    Article  CAS  Google Scholar 

  10. Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 2008; 141: 80–83.

    Article  Google Scholar 

  11. Mesa R, Nagorney DS, Schwager S, Allred J, Tefferi A . Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361–370.

    Article  Google Scholar 

  12. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 43: 1144–1148.

    Article  Google Scholar 

  13. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  Google Scholar 

  14. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation in JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  Google Scholar 

  15. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating muation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  Google Scholar 

  16. Verstovsek S, Kantarjian H, Pardanani A, Thomas D, Cortes J, Mesa R et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 1762.

  17. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research center Collaborative Study. Blood 1999; 93: 2831–2838.

    CAS  PubMed  Google Scholar 

  18. Daly A, Song K, Nevill T, Nantel S, Toze C, Hogge D et al. Stem cell transplantation for myelofibrosis: a report from two canadian centers. Bone Marrow Transplant 2003; 32: 35–40.

    Article  CAS  Google Scholar 

  19. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.

    Article  CAS  Google Scholar 

  20. Ditchkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH . Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34: 807–813.

    Article  Google Scholar 

  21. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.

    Article  CAS  Google Scholar 

  22. Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 12: 1161–1168.

    Article  Google Scholar 

  23. Hessling J, Kroger N, Werner M, Zabelina T, Hansen A, Kordes U et al. Dose reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769–772.

    Article  Google Scholar 

  24. Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367–373.

    Article  CAS  Google Scholar 

  25. Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690–697.

    Article  Google Scholar 

  26. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–4119.

    Article  CAS  Google Scholar 

  27. Patriarca F, Bacigalupo A, Speretto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano di Midollo Osseo (GITMO). Haematologica 2008; 93: 1514–1522.

    Article  CAS  Google Scholar 

  28. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  29. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  30. Kroger N, Thiele J, Zander A, Schwertefeger R, Kobbe G, Bornhauser M et al. Rapid regression of bone marrow fibrosis after dose reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35: 1719–1722.

    Article  Google Scholar 

Download references

Acknowledgements

We wish to thank the data managers and transplant physicians at the following centres for providing data and responding to requests for further information: University College Hospital London, Hammersmith Hospital London, Glasgow Royal Infirmary, Bristol Royal Hospital, Queen Elizabeth Hospital Birmingham, Royal Free Hospital London, St James's Hospital Dublin, Nottingham City Hospital, John Radcliffe Hospital Oxford, St George's Hospital London, Addenbroooke's Hospital Cambridge, Southampton General Hospital, Belfast City Hospital, Royal Liverpool University Hospital, Leicester Royal Infirmary, Christie Hospital Manchester and Derriford Hospital Plymouth.

Author information

Authors and Affiliations

  1. Cancer Science Institute, National University of Singapore, Singapore

    W A Stewart

  2. British Society for Blood and Marrow Transplantation Data Registry, Guy's Hospital, London, UK

    R Pearce & K E Kirkland

  3. Department of Haematology, Christie Hospital, Manchester, UK

    A Bloor

  4. Department of Haematology, University College Hospital London, London, UK

    K Thomson

  5. Department of Haematology, Imperial College London, Hammersmith Hospital Campus, London, UK

    J Apperley

  6. Bone Marrow Transplant Unit, Glasgow Royal Infirmary, Glasgow, UK

    G McQuaker

  7. Adult BMT Unit, United Bristol Healthcare Trust, Bristol, UK

    D I Marks

  8. Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK

    C Craddock

  9. Department of Haematology, St James's Hospital and Trinity College Dublin, Dublin, Ireland

    S McCann

  10. The Centre for Clinical Haematology, Nottingham University Hospital (City Campus), Nottingham, UK

    N Russell

  11. Department of Haematology, St James's Institute of Oncology, Leeds Teaching Hospital Trust, Leeds, UK

    G Cook

  12. Department of Haematology, Royal Free and University College London Medical School, London, UK

    P D Kottaridis

Authors
  1. W A Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Pearce
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K E Kirkland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Bloor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Thomson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G McQuaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D I Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Craddock
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S McCann
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P D Kottaridis
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the British Society for Blood and Marrow Transplantation

Corresponding author

Correspondence to P D Kottaridis.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, W., Pearce, R., Kirkland, K. et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 45, 1587–1593 (2010). https://doi.org/10.1038/bmt.2010.14

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.14

Keywords

This article is cited by

Search

Advanced search

Quick links